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ABSTRACT
Introduction: Infliximab is registered for the
treatment of moderate-to-severe active
ulcerative colitis (UC) adult patients who have
had an inadequate response, or are intolerant,
or have medical contraindications to therapy
including corticosteroids and 5-aminosalicylates
or thiopurines (6-mercaptopurine [6-MP] or
azathioprine [AZA]). The authors estimate the
costs and effects and evaluate the cost-
effectiveness of infliximab at the licensed dose
of 5 mg/kg versus cyclosporine or surgery for the
treatment of adult Dutch patients hospitalized
with acute exacerbations of UC, refractory to
intravenous steroids.
Method: An existing decision analytical model
was updated to simulate disease progression of
hospitalized UC patients in the Netherlands,
refractory to intravenous corticosteroids, and to
estimate the costs and benefits associated with
infliximab compared to cyclosporine and
surgery over a 1-year time horizon. Colectomy
rates were derived from infliximab and
cyclosporine randomized trials and synthesized
using multiple treatment comparison methods.
The utility estimates associated with health
states of ulcerative colitis patients were
obtained from the literature. Resource use and
drug use frequencies as well as unit costs were
obtained from Dutch sources. The primary
effectiveness measure used in the analysis was
quality-adjusted life years (QALYs).
Results: For a typical UC patient with body
weight of 70 kg, the costs of treatment with
infliximab, cyclosporine, and surgery over a
1-year treatment period were €17,062, €14,784,
€13,979, respectively. The associated numbers of
QALYs were 0.80, 0.70, and 0.58 for infliximab,
cyclosporine, and surgery respectively. The
incremental cost-effectiveness ratio for infliximab
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was €24,277 per QALY gained compared to
cyclosporine, and €14,639 per QALY gained
compared to surgery.
Conclusions: Infliximab induction regimen
appears to be a cost-effective treatment option
in comparison to cyclosporine and surgery for
hospitalized patients with acute exacerbations




The Netherlands; Ulcerative colitis
INTRODUCTION
Ulcerative colitis (UC) is characterized by
chronic inflammation of the mucosa of the
colon. The symptoms of UC vary according to
the extent and severity of the inflammation.
Symptoms include bloody diarrhea, abdominal
pain, anemia, fatigue, weight loss, rectal
bleeding, and loss of appetite. A Dutch study
demonstrated that UC influences daily
functioning, predominantly when patients
have a high disease activity [1]. Especially, loss
of energy as a consequence of an active disease
is an important limitation in daily activity for
UC patients. Patients with UC experience lower
quality of life because of loss of energy, negative
self-image, social fear, dealing with a chronic
disease, and lack of information provided by
health care staff [2, 3]. Quality of life for UC
patients is affected by both the symptoms
associated with disease and by treatments and
related adverse effects [4].
According to the Dutch Health Care
Insurance Board, it is estimated that the
incidence of UC is approximately 10–12 per
100,000 per year with a reported prevalence of
70–150 per 100,000 [5]. Based on these
prevalence figures, there are between 17,000
and 35,000 people in the Netherlands with UC.
Cost of illness of inflammatory bowel disease
(IBD) in the Netherlands in 2005 was €118.6
million; 0.2% of the Dutch healthcare budget.
Most costs were incurred by the people aged
25–44 years and 70% of all costs of illness were
spent on hospital care and specialists [6].
According to Odes et al. [7] the mean annual
total expenditure on health care was €1,524 per
patient year for UC in Europe and Israel.
Furthermore, among Dutch patients with IBD,
labor force participation was 6.5% lower and
chronic work disability 17.1% higher than the
age and gender matched general population [8].
Infliximab is an inhibitor of tumor necrosis
factor-a (TNF-a), a cytokine that plays an
important role in the pathogenesis of UC [9].
Infliximab is registered for treatment of
moderately-to-severely active UC in adult
patients who have had an inadequate response
to conventional therapy including corticosteroids
and 5-aminosalicylates or 6-mercaptopurine
(6-MP) or azathioprine (AZA), or who are
intolerant to, or have medical contraindications
for such therapies in randomized controlled trials,
Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and
ACT 2) [10]. Infliximab has also been used to
avoid surgery in patients with acute exacerbations
of UC [11, 12].
Infliximab induction regimen was shown to
be a cost-effective treatment option compared
to surgery for UC patients hospitalized with an
acute exacerbation in the UK [13]. Scheduled
maintenance treatment with infliximab has
been shown to be cost-effective in moderate-
to-severe UC patients [14].
The objective of this study is to estimate the
costs and effects and evaluate the cost-
effectiveness of infliximab at the licensed dose
of 5 mg/kg versus cyclosporine or surgery for
the treatment of adult Dutch patients
46 Biol Ther (2013) 3:45–60
123
hospitalized with acute exacerbations of UC,
refractory to intravenous (IV) steroids.
METHODS
Model Overview
A decision analytic model, developed earlier
[13], was used to simulate the progression
of a hypothetical cohort of Dutch patients
hospitalized with an exacerbation of UC and
treated with cyclosporine or surgery and to
track the associated costs and outcomes. The
model was updated and adapted to conform
to the treatment practice in the Netherlands
[2, 15, 16]. The base case time horizon of 1 year
was used based on the observation periods of
available published evidence [10, 11, 17] and
was varied up to 10 years in the sensitivity
analysis. Because of different characterization of
treatment outcomes (see Fig. 1) the base case
period was divided into two treatment cycles
(0–3 and 4–12 months) and a decision tree
structure was considered more appropriate
than a Markov modeling framework.
The initial model cohort consisted of
severely active UC Dutch adult patients with
an average weight of 70 kg hospitalized with
acute exacerbation of the disease and not
responding to 72 h of IV steroid therapy.
These patients received one of the three
treatments: infliximab, cyclosporine, or
surgical intervention. The treatment options
and the treatment pathways are shown in Fig. 1.
The goal of medical treatments was to avoid
colectomy and induce remission.
After drug treatment, patients could achieve
remission or fail treatment and progress to
surgery. In the absence of evidence on patient
outcomes following different treatments, all
patients achieving remission were assumed to
maintain symptom free remission during the
first cycle. During the second cycle, patients
achieving remission either maintained the
remission for the rest of the 12 months period
or lost response and underwent colectomy.
After surgery, patients could achieve surgical
remission or suffer from surgical complications,
undergo repeat surgery, and achieve surgical
remission afterwards. Once patients were in the
surgical remission, they were assumed to stay in
that state. It was assumed that postsurgery
complications would occur immediately after
surgery and therefore in the same cycle as
surgery. Patients treated for postsurgery
complications were assumed to recover in the
following cycle, achieve postsurgical remission
and remain in remission for the rest of the
analysis. Schematic presentation of the base
case decision tree model is shown in Fig. 2.
The economic analysis was conducted with
the perspective of the Nederland national payer
for the reference year 2010 following Dutch
guidelines for pharmacoeconomic evaluations
Fig. 1 Treatment options and treatment pathways. Aza azathioprine, Ciclo cyclosporine, IFX inﬂiximab, IV intravenous
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[18, 19]. Costs and effects were discounted at 4
and 1.5% a year respectively. The primary
effectiveness measure used in the analysis was
quality-adjusted life years (QALYs).
To study the effects of the uncertainty
around the modeling parameters on the final
outcomes, deterministic as well as probabilistic
sensitivity analyses were carried out.
Deterministic sensitivity analyses were carried
out by setting the model parameters (baseline
body weight, utility weights and time horizon)
equal to more extreme predetermined values.
For the probabilistic sensitivity analysis,
probability distributions of input parameters
(transition probabilities, costs, utilities) were
used. Beta distribution was used to model the
variability in transition probabilities and
utilities and Gamma distribution for costs.
Long-term Follow-up
Beyond the first year, a Markov model was used
to predict the outcomes over a period of up to
10 years as part of the sensitivity analysis to
assess the uncertainty around the time horizon
(see Fig. 3). The probabilities of colectomy for
the period 4–12 months were repeated to model
the experience of patients in remission after the
first year. Patients could remain in remission
indefinitely or lose response and undergo
Fig. 2 Decision tree model for patients with acute exacerbations of ulcerative colitis (UC) (health states and decisions for
cyclosporine and inﬂiximab treatments are similar)
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surgery. Here again, patients could achieve
surgical remission or suffer from surgical
complications, undergo repeat surgery with
the possibility of achieving surgical remission
afterwards.
Treatment Comparators and Clinical
Practice
According to the Dutch guidelines for
pharmacoeconomic research [18], a drug
should be compared with the standard or usual
treatment for which effectiveness has been
proven. UC patients hospitalized with an acute
exacerbation currently receive IV corticosteroids
(for up to 72 h) in addition to their existing
immunomodulator therapy. A total of 25% of
these patients fail IV steroids and require further
medical intervention [11, 20]. Following Dutch
guidelines, cyclosporine and surgery were
chosen as the treatment comparators [2, 20–23].
In general, patients with an acute exacerbation
of UC will receive 72 h 40–60 mg/day IV
prednisolone. Patients refractory to the initial
treatment are assumed to receive one of the
three identified treatment strategies comprising
infliximab, cyclosporine or surgical intervention.
Responders to medical treatments were assumed
to be discharged from the hospital on the 10th
day and moved to an outpatient setting. Patients
not responding to medical treatments on or
before the 10th day were assumed to progress to
surgery.
Infliximab treatment included a first infusion
of 5 mg/kg of infliximab on day 4, followed by
additional 5 mg/kg infusion doses at week 2 and
6 after the first infusion. Patients on infliximab
are expected to respond within 7 days of the first
infusion. Following discharge from hospital, all
infliximab responders received oral azathioprine
(2 mg/kg) for the rest of the 3-month period.
Patients receiving cyclosporine are given a
2 mg/kg daily dose of IV cyclosporine starting
on day 4 for a period of 7 days. Following
discharge from the hospital, cyclosporine
responders are switched to an oral emulsion of
cyclosporine (5 mg/kg/day) until 3 months
(80 days in total) as a bridge to maintenance
therapy with immunomodulator azathioprine
(2 mg/kg/day) alone.
All patients on medical interventions who are
still in remission after the first 3 months receive
Fig. 3 Structure of Markov model for patients in remission after the ﬁrst year
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the combination maintenance treatment of oral
corticosteroids and azathioprine in the same dose
as the first 3 months for the remainder of the
analysis time frame [2].
Patients undergoing surgical intervention do
not receive concomitant medication [2].
Outcomes and Transition Probabilities
The transition probabilities determined the
proportion of patients in each health state
over time. Because of the lack of any head-to-
head trials between infliximab and
cyclosporine, studies with placebo/steroids as a
common comparator were selected. Colectomy
rates used in the model were based on four
studies which included acute severe and
moderately severe UC patients admitted in a
hospital [11, 12, 17, 24]. The patients in three
studies [11, 12, 17, 24] were nonresponsive to IV
corticosteroids whereas the patients in the
fourth study [17] were not steroid refractory
and received steroid therapy as a comparator
instead of placebo.
The cumulated relative risk of disease
progression on different treatment alternatives
was expressed as a relative risk of a surgical
procedure. For infliximab the efficacy estimates
were derived from studies by Ja¨rnerot et al. [11]
and Sands et al. [12] whereas for cyclosporine
they were derived from D’Haens et al. [17] and
Lichtiger et al. [24]. The overall combined risks
were determined by an indirect comparison of
available clinical trials [13, 25, 26]. The analysis
dataset and the synthesized cumulative
probabilities of colectomy at 3 and 12 months
are presented in Tables 1 and 2 for Reference
[11, 12, 17, 21, 24].
The joint posterior distribution obtained
from the indirect comparison was used to
model the joint uncertainty in the transition
probabilities to surgery, here by accounting for
potential correlation between these parameters
[27]. The model was run to simulated 1,000
cohorts of 1,000 patients in each treatment arm.
Surgical Complications
Postoperative wound infection, postoperative
rectal stump complications, postoperative
bleeding, postoperative sepsis, anastomotic
leakage, small bowel obstruction and stoma
complications were included to define the
surgical complication. The overall aggregate
rate of surgical complications was derived
from the UK IBD audit [21].
Patient Mortality
Patient mortality was excluded from the model
as a Dutch study shows that overall mortality
rates for UC patients are comparable to the
background population [28]. Not including
mortality can be labeled as a conservative
approach especially in the case where there
might be a mortality risk associated with the
surgical procedure in these UC patients.
Risk of Side Effects
The risk of side effects associated with either
treatment with infliximab or cyclosporine
was not included. Infusion-related reactions
were the most common adverse reactions
reported for infliximab. In clinical studies,
approximately 20% of infliximab-treated
patients experienced an infusion-related effect,
only 3% of the patients discontinued treatment
due to these effects and all patients recovered [2].
Other common (C1/100 to \1/10) side effects
are headache, viral infections, fever, abdominal
pain, rash, and increased transaminases [9]. Side
effects associated with cyclosporine that occur
very frequently (C1/10) are renal dysfunction,
50 Biol Ther (2013) 3:45–60
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hypertension, hyperlipidemia, headache, and
tremor [29]. Renal dysfunction in particular,
with its high frequency, is a potential serious
complication and should be monitored
adequately [2]. Not including risk of side effects
is most likely not in favor of infliximab
concerning patients’ quality of life as
cyclosporine has a worse side effect profile
compared to infliximab.
UTILITIES
The health-related quality of life weights
associated with active UC, medical remission,






Ja¨rnerot et al. [11] Placebo 3 14 21
Inﬂiximab 3 7 24
Sands et al. [12] Placebo 3 3 3
Inﬂiximab 3 0 3
Lichtiger et al. [24] Placebo 3 4 9
Cyclosporine 3 3 11
D’Haens et al. [17] Placebo 3 3 15
Cyclosporine 3 3 14
Ja¨rnerot et al. [11] Placebo 12 1 7
Inﬂiximab 12 3 17
D’Haens et al. [17] Placebo 12 3 12
Cyclosporine 12 3 11
Table 2 Transition probabilities imputed in the models
Probability Estimate SE Source
Surgery 0–3 months
Inﬂiximab 0.23 0.042 Ja¨rnerot et al. [11] and Sands et al. [12]
Cyclosporine 0.58 0.049 D’Haens et al. [17] and Lichtiger et al. [24]
Surgery 4–12 months
Inﬂiximab 0.27 0.065 Ja¨rnerot et al. [11]
Cyclosporine 0.18 0.057 D’Haens et al. [17]
Surgical complicationsa 0.23 0.030 UK IBD Audit 2006 [21]
SE standard error
a Sum of postoperative wound infection, postoperative rectal stump complications, postoperative bleeding, postoperative
sepsis, anastomotic leakage, small bowel obstruction and stoma complications
Biol Ther (2013) 3:45–60 51
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surgical remission and surgical complications
were obtained from the literature. The utility
weights used in the base case analysis were
derived from a UC patient survey carried out in
Cardiff Hospital using the EQ-5D (Health
outcomes data repository [HODaR]) [30]. Scores
were converted into utility measures using a
standard algorithm based on preferences from
the general public [31]. Patient utilities were
classified by indexing them with simple clinical
colitis activity index (SCAI), into remission
(SCAI: 0–2) and active UC (SCAI: 3 and above)
[32]. Separate sets of utilities were available for
ileal pouch anal anastomosis (IPAA) surgery and
ileostomy, therefore a weighted average (29%
IPAA, 71% ileostomy) was used as utility
for surgical remission. This study did not
capture utilities associated with postsurgery
complications and was assumed to be the same
as that of active UC patients. Health state utilities
were also available from Arseneau et al. [33].
However, these utilities were based on patient
preferences instead of general public estimates
and were used in the sensitivity analysis. Table 3
[33] summarizes health state utility estimates
used in the economic evaluation.
COSTS
In this pharmacoeconomic analysis, direct
medical costs were included because reliable
data on direct nonmedical costs were not
available. Direct medical costs include drug
costs and healthcare resource use costs
(consultant visits, hospital stay, surgery,
endoscopy, therapeutic drug monitoring, and
daycare). Indirect costs inside the health care
system which are not related to the active drug
treatment were excluded. IBD patients in the
Netherlands are related to lower labor
participation rates and higher chronic work
disability compared to the age- and gender-
matched general population [8]; however, there
are no data that measure the effect of treatment
on the productivity losses. It is more likely that
comparator treatments, which result in more
surgeries and hospital days, lead to more
production losses. Therefore, not including
productivity losses may be labeled as a
conservative approach.
All unit healthcare costs were based on the
Dutch Manual for costing research [34] and
accompanying unit cost table of the Health
Care Insurance Board [5]. Costs were adjusted to
the 2010 price level using the harmonized
consumer price index figures [35].
Drug Acquisition and Administration
Costs
The costs of comparator treatments and
concomitant medications used in the analysis
Table 3 Utility estimates associated with health states of ulcerative colitis patients
HODaR (EQ-5D) Arseneau (TTO) [33] Arseneau (VRS) [33]
Mean (SE) Mean (SE) Mean (SE)
Remission 0.88 (0.039) 0.79 (0.059) 0.82 (0.055)
Active UC 0.42 (0.093) 0.49 (0.072) 0.41 (0.071)
Surgical remission 0.60 (0.094) 0.63 (0.070) 0.50 (0.072)
Surgical complications 0.42 (0.093) 0.49 (0.072) 0.41 (0.071)
HODaR health outcomes data repository, SE standard error, TTO time tradeoff, UC ulcerative colitis, VRS visual rating
scale
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were based on the average doses used in the
clinical trials. The unit costs for drugs were
obtained from the ‘KNMP (Koninklijke
Nederlandse Maatschappij ter bevordering der
Pharmacie) taxe September 2010’ [36].
Prednisolone, infliximab and cyclosporine are
all administered IV in the hospital whereas
patients take oral cyclosporine and
azathioprine at home. The unit costs of drug
acquisition and administration and the
estimated total costs per day, assuming an
average patient body weight of 70 kg, are
shown in Table 4 [36, 37]. The number of
days of treatment and the total drug costs for
the infliximab, cyclosporine, and surgery
treatment groups during the first 3 month
cycle of treatment are shown in Table 5. Any
patient undergoing surgical intervention had
no need for further medication [2]. After the
first 3 months, only patients who were still in
remission received maintenance treatment of
azathioprine in the same dose as the first
3 months.
Surgical Procedures
Surgery consisting of a proctocolectomy with an
ileoanal pouch, is standard treatment for
patients not responding to therapy, usually
performed in two separate operations [2, 15,
16]. Costs for these procedures were not
available from Dutch sources; therefore costs
of comparable procedures from the UK were
used in the model. Costs are comprised of two
surgical interventions, ileostomy (€1,320.38)
and colectomy with ileorectal anastomosis
(€2,728.64) [26].
Healthcare Resource Use
Healthcare resource unit costs (2010 figures),
number of days of use and overall cost
estimates in the first 3 months are shown in
Table 6 [26, 34].
All patients with an acute exacerbation are
assumed to have an endoscopy when they are
admitted into the hospital to evaluate the
Table 4 Drug cost estimates per day for a 70 kg patient in 2010
Prednisolone IV Inﬂiximab IV Cyclosporine IV Cyclosporine PO Azathioprine PO
Unit costs [36] (AIPa) €26.40 €647.08 €33.14 €159.36 €11.66
Pack size 10 1 10 50 50
Strength 25 mg/mL 100 mg/mL 50 mg/mL 100 mg/mL 50 mg
Dose 60 mg 5 mg/kg 2 mg/kg 5 mg/kg 2 mg/kg
Drug costs/day (AIPa) €6.34 €2,264.78 €9.28 €11.16 €0.65
Costs/90 days – – – €1,003.97 €58.77
Prescription cost [37] – – – €7.91 €7.91
Clawback (8.53%) [37] – – – €6.80 €5.01
VAT (6%) – – – €60.30 €3.70
Drug cost/daya €6.34 €2,264.78 €9.28 €11.84 €0.73
IV intravenous, PO per os (oral administration)
a Apotheek inkoopprijs
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severity of UC and after achieving (surgical)
remission in the first 3 months. Costs for a
diagnostic endoscopy were calculated by taking
the average of a colonoscopy (€307.78) and a
sigmoidoscopy (€180.58), since both techniques
are used for diagnosis of the exacerbation
[2, 16]. Ongoing surveillance with endoscopy
only starts 8 years after diagnosis of UC or when
dysplasia was already present at time of surgery.
Surveillance would take place three times in the
first decade [2, 38]. These costs are not inserted
in the model, since they have a minor impact
on total costs.
The frequency of consultant visits during the
first 3 months is shown in Table 7 whereas the
ongoing consultant visits are assumed to take
place once every 3 months.
Patients successfully treated with infliximab
or cyclosporine are discharged from the hospital
after 10 days. This estimate was based on the
clinical trials of infliximab and cyclosporine
and includes the first 3 days of IV steroids and a
Table 5 Total drug treatment cost (2010 ﬁgures) estimates during the ﬁrst 3 months based on a typical 70 kg patient
Drug Costs/day (€) Days of treatment, ﬁrst 3 months
Inﬂiximab Cyclosporine Surgery
Inﬂiximab IV 2,264.78 3 0 0
Cyclosporine IV 9.28 0 7 0
Cyclosporine PO 11.84 0 80 0
Prednisolone IV 6.34 3 3 3
Azathioprine PO 0.73 80 80 0
Total costs (ﬁrst 3 months) €6,871.45 €1,089.07 €19.01
IV intravenous, PO per os (oral administration)
Table 6 Healthcare resource unit costs (2010 ﬁgures), number of days of use and overall cost estimates in the ﬁrst 3 months
Resource Costs/unit (€) Days of use, ﬁrst 3 months
Inﬂiximab Cyclosporine Surgery
Consult visit [34] 70.65 2 2 3
Hospital day [34] 402.62 10 10 20
Surgery [26] 4,049.02 0 0 1
Diagnostic endoscopy [26] 244.18 2 2 2
TDM cyclosporine [26] 104.65 0 10 0
Daycare inﬂiximab [34] 256.66 2 0 0
Total costs (ﬁrst 3 months) €5,169.21 €5,702.37 €12,801.81
Consultant visit and hospital day costs are the weighted averages of these costs in general and academic settings. Diagnostic
endoscopy cost is the average of the colonoscopy and sigmoidoscopy procedure costs. Surgery cost is the sum of the costs of
colectomy with ileorectal anastomosis and ileostomy procedures
TDM therapeutic drug monitoring
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7-day recovery period on rescue treatment
following steroid failure. These trials reported
that patients have a mean response time of
7 days following the initiation of treatment
(range 1–14 days) [11, 12, 24] after which they
are assumed to be discharged from the hospital.
In case of surgical complications (e.g.,
postoperative wound infection, small bowel
obstruction), an additional 10 days in the
general ward are assumed to reflect the cost
for the treatment of these complications.
Therapeutic drug monitoring of cyclosporine
is performed using chromatography as this
method is the standard for cyclosporine
measurement [39]. Furthermore cyclosporine
levels will be determined as scheduled in
Lichtiger et al. [24] and Ouakaa-Kchaou et al.
[40]. When patients receive IV cyclosporine,
their cyclosporine levels are measured every
2 days. While on oral cyclosporine, patients’
cyclosporine levels should be tested weekly for
the first month, biweekly for the second month,
and then every 3–4 weeks. Unit costs for a
daycare visit are assumed to reflect the costs
for the second and third administration of
infliximab which occur when patients have
already been discharged from the hospital.
RESULTS
The base case cost-effectiveness analyses
comparing infliximab with cyclosporine and
surgery are presented in Table 7. When
infliximab is compared to cyclosporine, the
model predicts a cost-effectiveness ratio of
€24,277 per QALY, based on incremental
QALYs of 0.09 and incremental costs of €2,278.
In the comparison of infliximab versus surgery
the model estimates a cost-effectiveness ratio of
€14,639 per QALY, based on incremental QALYs
of 0.21 and incremental costs of €3,083. One-
way sensitivity analyses showed that the results
were sensitive to changes in baseline body
weight, utility estimates, and the time horizon
of analysis (Table 8). The results of probabilistic
sensitivity analysis are displayed in a cost-
effectiveness acceptability curve in Fig. 4. The
acceptability curve showed that there was a 55
and 79% chance that infliximab was cost-
effective compared to cyclosporine and
surgery, respectively, at the willingness to pay
threshold of €30,000 per QALY.
DISCUSSION
Infliximab induction regimen was shown to be
cost-effective treatment option for UC patients
hospitalized with an acute exacerbation in the
UK [13]. Using an updated version of the UK
model, this pharmacoeconomic analysis
estimated the costs and effects of infliximab
versus cyclosporine and surgery as a rescue
therapy for Dutch patients hospitalized with
acute exacerbation of UC.
Table 7 Base-case results
Treatment Cost (€) QALY D Cost (€) D QALYs ICER (€)
Inﬂiximab 17,062 0.80 – – –
Cyclosporine 14,784 0.70 2,278 0.09 24,277
Surgery 13,979 0.58 3,083 0.21 14,639
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
Biol Ther (2013) 3:45–60 55
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Sensitivity analyses suggest that the patient
weight is an important factor affecting the
cost-effectiveness of infliximab. This analysis
used 70 kg as the weight of a typical adult UC
patient; however the steroid refractory patients
hospitalized with acute exacerbation might
weigh significantly less than the patients in an
outpatient setting thereby resulting in
improved cost-effectiveness for infliximab.
The base-case analysis used an analysis time
horizon of 1 year. The authors explored the
impact of increasing the time horizon 5 and
10 years using constant treatment effects to
evaluate the long-term costs and benefits.
Note that the long-term extrapolation is
based on the efficacy estimates from small
sample sizes and is subject to a high degree of
uncertainty.
Wherever data were not available,
assumptions used were conservative adversely
affecting infliximab’s case against alternative
treatments. For example, the full licensed
induction dose of 5 mg/kg infliximab
(infusions at week 0, 2, and 6) was used in this
analysis whereas the colectomy rates pertained
to a single infusion of infliximab. The authors
assumed that the full induction dose would be
at least as effective as a single infusion of
infliximab. However, there is evidence that
two or more infusions may be more effective
than one single infusion [41]. Therefore the
results based on the efficacy estimates of
infliximab used in this analysis are likely to be
conservative.
Patient mortality and the risk of side effects
were excluded from the model because no
Table 8 One-way sensitivity analysis results
Scenario Value D Costs D QALYs ICER
Changing utilities
Inﬂiximab versus cyclosporine TTO €2,278 0.06 €35,743
VRS €2,278 0.10 €22,862
Inﬂiximab versus surgery TTO €3,083 0.14 €22,440
VRS €3,083 0.23 €13,581
Changing baseline weight
Inﬂiximab versus cyclosporine 60 kg €1,515 0.09 €16,145
80 kg €3,041 0.09 €32,408
Inﬂiximab versus surgery 60 kg €2,243 0.21 €10,648
80 kg €3,924 0.21 €18,630
Changing time horizon
Inﬂiximab versus cyclosporine 5 years €5,277 0.18 €29,647
10 years €5,370 0.16 €34,258
Inﬂiximab versus surgery 5 years €9,114 0.53 €17,204
10 years €10,182 0.59 €17,191
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, TTO time tradeoff, VRS visual rating scale
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information was available on the immediate
side effects of infliximab in UC patients (ACT 1
and ACT 2) [10]. Not including these events
can be considered conservative as it is expected
that they occur less frequently when patients
are treated with infliximab compared to
treatment with cyclosporine or surgery.
Cyclosporine is associated with a worse side
effect profile than infliximab and surgery might
be involved with a mortality risk. Not including
risk of side effects and mortality is likely to
result in conservative estimates of the cost-
effectiveness of infliximab versus cyclosporine
and surgery.
In the absence of reliable data, productivity
losses were not included in the analysis. It is
more likely that comparator treatments, which
result in more surgeries and hospital days, lead
to more production losses. Therefore, not
including productivity losses may also be
labeled as a conservative approach.
The current analysis has several limitations.
In general, a model is an abstraction of reality
and not expected to capture all aspects of disease
progression under alternative treatment
strategies. In the absence of direct comparative
data on infliximab versus cyclosporine use in
moderate to severe UC patients, an indirect
comparison was undertaken with placebo/
steroids as the common comparator. One of
the studies (D’Haens et al. [17]) used in the
indirect comparison was not appropriate
because neither the population nor the
comparator treatment was in line with the
Fig. 4 Acceptability curve showing the probability that inﬂiximab is cost-effective versus cyclosporine and surgery at a range
of willingness to pay thresholds
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other trials for infliximab and cyclosporine. The
included patient population was not steroid
refractory and cyclosporine treatment was
compared to treatment with steroids instead of
placebo. The D’Haens et al. [17] study was
included as the best available evidence because
no data were available for medium and long
term efficacy of cyclosporine. The efficacy
estimates were based on a small number of
trials with small sample sizes introducing
significant uncertainty in results. Several
univariate and extensive probabilistic
sensitivity analysis were conducted to explore
uncertainty around the results. The results were
exploratory in nature and should be interpreted
with caution.
CONCLUSION
Infliximab 5 mg/kg is an effective and safe
rescue therapy in patients hospitalized and
experiencing an acute exacerbation of UC. As
demonstrated by this economic analysis,
infliximab induction regimen appears to be a
cost-effective treatment option in comparison
to cyclosporine and surgery for hospitalized
patients with acute exacerbations of UC,
refractory to IV corticosteroids, in the
Netherlands.
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